Gujarat Themis Seeks Approval for Rajneesh Anand's Director Appointment
Gujarat Themis Biosyn Limited is seeking shareholder approval for Mr. Rajneesh Anand's appointment as a Non-Executive Non-Independent Director for a five-year term from November 10, 2025, to November 9, 2030. Remote e-voting is open from January 8 to February 6, 2026. Mr. Anand will receive ₹10 lakh monthly as professional fees.
The appointment of a director, especially one with significant proposed remuneration and responsibilities, can have a medium-term impact on the company's strategic direction and governance.
The announcement pertains to a routine corporate action, the appointment of a director, which is a standard procedure and does not inherently indicate positive or negative performance or outlook for the company.
Gujarat Themis Biosyn Limited has initiated a postal ballot process to seek shareholder approval for the appointment of Mr. Rajneesh Anand as a Non-Executive Non-Independent Director. The voting period commences on January 8, 2026, and concludes on February 6, 2026. The results are expected to be declared by February 10, 2026.
Mr. Anand's appointment is proposed for a term of five years, from November 10, 2025, to November 9, 2030. He will be eligible for reappointment even after turning 75 on March 5, 2029, subject to shareholder approval. He will receive a professional fee of ₹10 lakh per month for his advisory and supervisory services, focusing on technical operations, manufacturing, regulatory affairs, strategy, and business development. He will not receive sitting fees or profit commission.
The company is facilitating remote e-voting for shareholders, with detailed instructions provided on their website and the CDSL e-voting platform. The cut-off date for determining eligible shareholders was January 2, 2026.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.